Development of Neuroendocrine Tumors in Patients with a Family History of NET or Any Other Cancer Abstract #1663

Introduction: Neuroendocrine tumors are rare. A very little knowledge is known about its risk factors. Studies have shown that NETs may develop as a part of hereditary syndromes.
Aim(s): We aim to investigate the development of neuroendocrine tumors in patients with a family history of NET or any other cancer
Materials and methods: A retrospective study was conducted in Sir Ganga Ram Hospital, Lahore. 500 patients with NET were identified and 500 healthy controls were made. Questionnaire was filled containing the data including family history of smoking and alcohol use, family history of NET and cancer and personal medical history. The study was restricted to first degree relatives only.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Arooj Fatima

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1750 Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center
Introduction: Sunitinib is indicated in the treatment of patients with advanced progressive pancreatic neuroendocrine tumors (pNETs).Its experience as first line therapy is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: doctor Belabdi Djihed
#1227 Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)
Introduction: Aberrant DNA methylation plays an role in the pathogenesis of many cancers, however little is known about its role in SINET development.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
#220 The Global mTOR Inhibitor Torin1 is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylases Inhibitors, in Suppressing Neuroendocrine Tumors Cell Proliferation
Introduction: Torin1, a new mTOR inhibitor that globally inhibits both mTORC1 and mTORC2, seems to impair cell growth and proliferation to a greater degree than rapamycin; its effects in NET cells are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Simona Grozinsky-Glasberg
#1661 Investigating the Increasing Incidence of Neuroendocrine Tumors in Pakistan as a Result of Increased Awareness
Introduction: Incidence of Neuroendocrine tumors has been increasing worldwide. The reasons for this rising incidence remains unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#1665 Exploring the Pathological and Clinical Characteristics of Neuroendocrine Tumors Located in Pancreas
Introduction: Neuroendocrine tumors are extremely rare and can be found anywhere in the body. Pancreas is the 2nd most common location where neuroendocrine tumors arise
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
Keywords: pNETs, diagnosis